Inside Market Data - Revere Increases Data Focus on Canadian BioPharm, MedTech Stocks ::
August 13, 2007
Inside Market Data
Vol 22 No 46
CONTENT FOCUS
San Francisco-based data and research provider Revere Data has expanded its range of data available on equities and related companies in the Canadian bio-pharmaceutical and medical technology sectors, where the vendor says it is seeing increased demand for information for clients to use in trading models.
The data, which includes information on companies’ product pipelines, the status of clinical trials, and information on companies’ relationships to competitors and suppliers, is being made available via the vendor’s Revere Research analysis platform and Revere RealTime data system. The data is also available as part of the vendor’s XML or CSV file-format Healthcare Events datafeed, which can be fed directly into firms’ databases or trading models, such as for index or statistical arbitrage strategies.
Some of the information is collected from company filings at the Toronto Stock Exchange, updates to company Websites and primary research conducted by Revere’s analysts, which is then mapped to related companies using Revere’s proprietary taxonomy. “Users can now get more visibility into Canada ... and Canadian traders can build peer groups to see how a domestic stock is performing against international competitors,” says Revere chief executive Kevin O’Brien.
O’Brien says that the Canadian market’s similarities to the US make the information easy for the vendor to map to its taxonomy, as well as to link to related US companies. Revere is currently working on collecting and mapping information on companies in the European and Asian markets into its products, he says.
The new data is aimed at traders, investment managers and quantitative trading operations that want to be able to predict the impact on the share price of a company—or its suppliers or competitors—based on product or drug trial news,which they can use on their trading desks or in trading models. O’Brien says the vendor is seeing demand from US and European traders, who want the data to predict the impact of any movements on their domestic stocks the following day.“Firms can build global trading strategies with a high degree of confidence in the data,” he says.“
Healthcare has traditionally been a difficult market to get visibility into companies, their products and what they treat,because it is a deep, complex marketplace,” O’Brien says. “But when news comes out, you see a massive amount of trading in those stocks…. We’ve been tracking these companies for five years, so if a company is approved or declined for a new drug ... our clients can trade [on that information] and get visibility into other companies with similar products.”
The vendor is also beta testing additional data fields with clients, including drug sales, patent expirations—when a drugbecomes generic and can be marketed by competitors, potentially impacting the original manufacturer’s revenues—andproduct information for around 200 of the biggest-selling drugs, mapped to their parent companies and rivals, and plans toformally release this soon. “The more you cross-link that data to our existing data, the better trading opportunities you canachieve,” O’Brien says.
Max Bowie
Vol 22 No 46
CONTENT FOCUS
San Francisco-based data and research provider Revere Data has expanded its range of data available on equities and related companies in the Canadian bio-pharmaceutical and medical technology sectors, where the vendor says it is seeing increased demand for information for clients to use in trading models.
The data, which includes information on companies’ product pipelines, the status of clinical trials, and information on companies’ relationships to competitors and suppliers, is being made available via the vendor’s Revere Research analysis platform and Revere RealTime data system. The data is also available as part of the vendor’s XML or CSV file-format Healthcare Events datafeed, which can be fed directly into firms’ databases or trading models, such as for index or statistical arbitrage strategies.
Some of the information is collected from company filings at the Toronto Stock Exchange, updates to company Websites and primary research conducted by Revere’s analysts, which is then mapped to related companies using Revere’s proprietary taxonomy. “Users can now get more visibility into Canada ... and Canadian traders can build peer groups to see how a domestic stock is performing against international competitors,” says Revere chief executive Kevin O’Brien.
O’Brien says that the Canadian market’s similarities to the US make the information easy for the vendor to map to its taxonomy, as well as to link to related US companies. Revere is currently working on collecting and mapping information on companies in the European and Asian markets into its products, he says.
The new data is aimed at traders, investment managers and quantitative trading operations that want to be able to predict the impact on the share price of a company—or its suppliers or competitors—based on product or drug trial news,which they can use on their trading desks or in trading models. O’Brien says the vendor is seeing demand from US and European traders, who want the data to predict the impact of any movements on their domestic stocks the following day.“Firms can build global trading strategies with a high degree of confidence in the data,” he says.“
Healthcare has traditionally been a difficult market to get visibility into companies, their products and what they treat,because it is a deep, complex marketplace,” O’Brien says. “But when news comes out, you see a massive amount of trading in those stocks…. We’ve been tracking these companies for five years, so if a company is approved or declined for a new drug ... our clients can trade [on that information] and get visibility into other companies with similar products.”
The vendor is also beta testing additional data fields with clients, including drug sales, patent expirations—when a drugbecomes generic and can be marketed by competitors, potentially impacting the original manufacturer’s revenues—andproduct information for around 200 of the biggest-selling drugs, mapped to their parent companies and rivals, and plans toformally release this soon. “The more you cross-link that data to our existing data, the better trading opportunities you canachieve,” O’Brien says.
Max Bowie